TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.

Sara A Hurvitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.